CSL Aktie

 

Brokers see long-term value despite differing views on near-term upside. The post Where could CSL shares go next? Here's what brokers are predicting appeared first on The Motley Fool Australia....

Find out what experts expect from CSL shares next. The post Up 36%: Can CSL shares keep rebounding? appeared first on The Motley Fool Australia....

Confidence has been shaken, but I think the long-term opportunity remains attractive. The post Is CSL a fallen ASX giant to buy in July? appeared first on The Motley Fool Australia....

MITSY vs. CSL: Which Stock Is the Better Value Option?...

The first week of FY27 has already started strongly. Here's whether BHP, CSL, and Goodman can keep it going. The post July is historically one of the best months for ASX shares. Can July FY27 deliver? appeared first on The Motley Fool Australia....

It certainly was a year to forget for this biotech giant. The post Why did CSL shares crash 50% in FY 2026? appeared first on The Motley Fool Australia....

This ASX blue chip is still trying to rebuild trust. The post Another CSL blow: Why this beaten-up ASX giant is sliding again appeared first on The Motley Fool Australia....

Let's see which stock the broker is bullish on this week. The post Bell Potter says this ASX healthcare share could rise 93% (It's not CSL) appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

THOUSAND OAKS (dpa-AFX) - Vifor Fresenius Medical Care Renal Pharma and CSL (CSL.AX) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended t......

Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the......

The European Medicines Agency recommended that CSL Ltd.'s drug Tavneos be pulled from the market after finding it was approved based on allegedly incorrect and misleading data, adding pressure to its US manufacturer, Amgen Inc....

Blackwattle Large Cap Quality Fund managers Joe Koh and Elan Miller explain their strategy. The post Why this fundie is overweight CSL and underweight CBA shares appeared first on The Motley Fool Australia....

CBA, Macquarie, and CSL each face a real test over a 20-year horizon. Here is why these three ASX blue chip shares could still pass it The post 3 ASX blue chip shares to buy and hold for the next 20 years appeared first on The Motley Fool Australia....

CSL's stunning fall has investors questioning its comeback prospects. The post Once untouchable, now unloved: What's up with CSL shares? appeared first on The Motley Fool Australia....

What happened to a CSL investment in the last year? The post $10,000 invested in CSL shares 12 months ago is now worth… appeared first on The Motley Fool Australia....

One is a reset healthcare giant, the other is a higher-risk payments stock with an improving earnings story. The post Why I'd buy CSL and Zip shares before they recover appeared first on The Motley Fool Australia....

Is sentiment changing course again? The post Down 54%: What should I do with my CSL shares now? appeared first on The Motley Fool Australia....

Investors no longer treat CSL like a flawless compounder, and that shift may be where the opportunity begins. The post Is this broker right about CSL shares? appeared first on The Motley Fool Australia....

Direct Lending Vertical Seeks to Capture Additional Opportunities Generated by the Firm's Existing Origination Engine & Credit Underwriting Framework Complements Flagship Strategic Lending Vertical, Building on Colbeck's 17-Year Track Record in Private CreditNEW YORK--(BUSINESS WIRE)--Colbeck Capital Management (“Colbeck”), a leading middle-market private credit firm focused on strategic lending, announced the launch of Colbeck Strategic Income (“CSI”), a new direct lending vertical, with an initial capital commitment of approximately $400 million. The launch of CSI demonstrates continued market demand for Colbeck's differentiated products and complements the firm's $1.7+ billion Colbeck Strategic Lending ("CSL") vertical.1 CSL closed its third fund in December 2024, 40% above its target given strong investor demand for alpha-generating capital solutions products. CSI focuses primarily on first-lien senior secured loans to middle-market companies experiencing their next stage transit...